Skip to content
value.today
Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSC
$263 Mmarket cap on Oct 28, 2026+31.7% since Jan 2024
Compare
World rank
#15,282
Revenue
$109 M
For year ending December-2025
Net income
$-10 M
-8.8% margin
SEC filing
Employees
78
As of March 1, 2026
SEC filing

Century Therapeutics, Inc. in brief

Century Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Philadelphia, Pennsylvania, USA. It was founded in 2018. Its market value was $263 M on 28 October 2026, which makes it the 15,282nd largest listed company in the world and the 2,978th largest in the USA on this site. In the year to December 2025 it had sales of $109 M and a net loss of $10 M. It employs about 78 people and Brent Pfeiffenberger is its chief executive. Its largest business segments by sales in 2025 were Single reportable segment (100%). Its shares trade under the symbol IPSC (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Century Therapeutics, Inc.

●Cutting-edge manufacturing capabilities intended to drive scale advantages and reduce cost of goods sold, or COGs, while minimizing product development and supply risk.

We are leveraging our expertise in cellular reprogramming, differentiation, genetic engineering, and manufacturing to develop therapies with the potential to provide enhanced clinical outcomes compared to existing cell therapy technologies and available therapeutic options. We are unique in the breadth of cell types we can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ ab T cells, or ab iT cells, and iPSC- natural killer cells, or iNK cells. We believe this capability enables optimal matching of cell characteristics to disease indication, ensuring we target the right cell for the right indication.

From the company's annual report filed with the US SEC: read the report

Century Therapeutics, Inc. timeline

4 events, 2018–2025
  1. 2018
  2. 🏁
    · approximate
    Founded
  3. 2021
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 21 June 2021; shares registered for exchange trading on 14 June 2021.
  6. 2025
  7. 💰
    Record revenue of $109 million
    FY2025, the highest of the 4 years on record.

Events of Century Therapeutics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$195 M$390 M$585 M$780 M2023202420252026

World rank over time

▼ down 4,062 places since 2022
2022-01-07: #11260#11,26020222022-12-25: #15066#15,06620222023-07-30: #18628#18,62820232024-01-05: #17900#17,90020242026-03-08: #7280#7,28020262026-08-01: #13660#13,66020262026-10-14: #15554#15,55420262026-10-28: #15322#15,3222026

Rank in USA: #2,868 (Jan 2022) · #3,094 (Dec 2022) · #3,689 (Jul 2023) · #3,248 (Jan 2024) · #1,285 (Mar 2026) · #2,756 (Aug 2026) · #3,006 (Oct 2026) · #2,982 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
2.4×
Price / book
1.7×
Free cash flow yield
-39.8%
Net margin
-8.8%
Operating margin
-15.8%
Return on equity
-6.0%
Liabilities / assets
29.0%
Net debt
$-74M
Revenue growth
+1556.4%
R&D / revenue
87.6%
Revenue per employee
$1.4 M
Profit per employee
$-123 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-54M—FY20Fiscal year ending Dec 2021: revenue —, net income $-96M—FY21Fiscal year ending Dec 2022: revenue $5M, net income $-131M$5MFY22Fiscal year ending Dec 2023: revenue $2M, net income $-137M$2MFY23Fiscal year ending Dec 2024: revenue $7M, net income $-127M$7MFY24Fiscal year ending Dec 2025: revenue $109M, net income $-10M$109MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$109M+1556.4%$-17M$-10M-8.8%
Dec 2024$7M+194.2%$-138M$-127M-1920.6%
Dec 2023$2M-56.9%$-147M$-137M-6101.3%
Dec 2022$5M—$-134M$-131M-2517.9%
Dec 2021——$-95M$-96M—
Dec 2020——$-54M$-54M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-104M$1M$-105M$-0.14—
Dec 2024$-110M$0M$-110M$-1.61—
Dec 2023$-88M$14M$-102M$-2.30—
Dec 2022$14M$31M$-17M$-2.96—
Dec 2021$-89M$45M$-134M$-2.96—
Dec 2020$-41M$10M$-51M$-7.16—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $4M, net income $-36M$4MDec ’24Three months to Mar 2025: revenue $109M, net income $77M$109MMar ’25Three months to Jun 2025: revenue —, net income $-33M—Jun ’25Three months to Sep 2025: revenue —, net income $-34M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-19M—Dec ’25Three months to Mar 2026: revenue —, net income $-22M—Mar ’26Three months to Jun 2026: revenue —, net income $-35M—Jun ’26Three months to Sep 2026: revenue —, net income $-23M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-23M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Century Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$109 M
Operating income
$-17 M
Net income
$-10 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$224 M
Total liabilities
$65 M
Total equity
$159 M

As of December-2025

Top 100 institutional investors in Century Therapeutics, Inc.#

As of Sep 30, 2026
102 institutions held 163.1 M shares (about 89.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 57.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Century Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Ra Capital Management, L.P.17,754,4300 (0.00%)9.78%$30 MNov 16, 2026
2TCG Crossover Management, LLC17,754,4300 (0.00%)9.78%$30 MNov 16, 2026
3Versant Venture Management, LLC12,166,1090 (0.00%)6.70%$21 MNov 13, 2026
4Deep Track Capital, LP9,462,6450 (0.00%)5.21%$16 MNov 16, 2026
5BlackRock, Inc.8,889,485+797,717 (+9.86%)4.90%$15 MNov 13, 2026
6RTW Investments, LP8,695,6520 (0.00%)4.79%$15 MNov 16, 2026
7Venrock Adviser, LLC8,695,6520 (0.00%)4.79%$15 MNov 16, 2026
8Commodore Capital LP8,695,6520 (0.00%)4.79%$15 MNov 16, 2026
9Millennium Management LLC6,054,973+1,859,992 (+44.34%)3.33%$10 MNov 16, 2026
10Vanguard Capital Management LLC5,692,587-11,093 (-0.19%)3.13%$10 MNov 13, 2026
11Woodline Partners LP5,663,346+1,405,816 (+33.02%)3.12%$10 MNov 16, 2026
12Balyasny Asset Management L.P.5,522,769-175 (0.00%)3.04%$9 MNov 16, 2026
13Point72 Asset Management, L.P.5,109,974+129,448 (+2.60%)2.81%$9 MNov 16, 2026
14Seven Fleet Capital Management LP4,421,739+73,913 (+1.70%)2.43%$8 MNov 16, 2026
15Trails Edge Capital Partners, LP4,134,9690 (0.00%)2.28%$7 MNov 16, 2026
16Spruce Street Capital LP4,059,0540 (0.00%)2.24%$7 MNov 13, 2026
17Adage Capital Partners GP, L.L.C.3,789,5380 (0.00%)2.09%$6 MNov 16, 2026
18Geode Capital Management, LLC2,870,994-108,535 (-3.64%)1.58%$5 MNov 6, 2026
19Stempoint Capital LP2,563,862+417,680 (+19.46%)1.41%$4 MNov 16, 2026
20Two Sigma Investments, LP2,560,953-138,060 (-5.12%)1.41%$4 MNov 16, 2026
21State Street Corp2,513,350+670,196 (+36.36%)1.38%$4 MNov 12, 2026
22DAFNA Capital Management LLC2,386,750-13,708 (-0.57%)1.31%$4 MNov 16, 2026
23Northern Trust Corp1,477,054-116,890 (-7.33%)0.81%$3 MNov 16, 2026
24Rock Springs Capital Management LP1,304,3470 (0.00%)0.72%$2 MNov 16, 2026
25Casdin Capital, LLC1,228,1900 (0.00%)0.68%$2 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Century Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Renaissance Technologies LLC1,074,200-183,500 (-14.59%)0.59%$2 MNov 12, 2026
27Vanguard Portfolio Management LLC1,035,026+19,643 (+1.93%)0.57%$2 MNov 13, 2026
28Longaeva Partners L.P.943,418New0.52%$2 MNov 16, 2026
29UBS Group AG804,439+572,030 (+246.13%)0.44%$1 MNov 10, 2026
30Vanguard Fiduciary Trust Co737,585+63 (+0.01%)0.41%$1 MNov 13, 2026
31Goldman Sachs Group Inc460,896+310,463 (+206.38%)0.25%$1 MNov 16, 2026
32Invesco Ltd.403,214+21,795 (+5.71%)0.22%$1 MNov 12, 2026
33Charles Schwab Investment Management Inc378,949+82 (+0.02%)0.21%$1 MNov 16, 2026
34Dimensional Fund Advisors LP318,535+47,043 (+17.33%)0.18%$1 MNov 4, 2026
35Bank of New York Mellon Corp299,0140 (0.00%)0.16%$1 MNov 5, 2026
36FMR LLC273,260+264,266 (+2938.25%)0.15%$0 MNov 10, 2026
37American Century Companies Inc232,301+58,239 (+33.46%)0.13%$0 MNov 12, 2026
38Nuveen, LLC163,5920 (0.00%)0.09%$0 MNov 10, 2026
39Morgan Stanley144,719+106,265 (+276.34%)0.08%$0 MNov 13, 2026
40Spark Investment Management LLC128,200+69,200 (+117.29%)0.07%$0 MNov 13, 2026
41Integrated Quantitative Investments LLC127,927New0.07%$0 MNov 13, 2026
42Rhumbline Advisers125,548-2,856 (-2.22%)0.07%$0 MNov 10, 2026
43Graham Capital Management, L.P.120,434New0.07%$0 MNov 16, 2026
44Squarepoint Ops LLC110,398+20,249 (+22.46%)0.06%$0 MNov 9, 2026
45Deutsche Bank AG\105,095-15,139 (-12.59%)0.06%$0 MNov 6, 2026
46Price T Rowe Associates Inc /MD/101,1640 (0.00%)0.06%$0 MNov 16, 2026
47Bank Of America Corp /de/101,113-57,780 (-36.36%)0.06%$0 MNov 16, 2026
48Raymond James Financial Inc91,3230 (0.00%)0.05%$0 MNov 12, 2026
49Citadel Advisors LLC84,660-41,810 (-33.06%)0.05%$0 MNov 16, 2026
50Wealth Enhancement Advisory Services, LLC78,186+356 (+0.46%)0.04%$0 MOct 13, 2026
51Royal Bank Of Canada77,014+70,631 (+1106.55%)0.04%$0 MNov 16, 2026
52Jpmorgan Chase & Co60,793+9,585 (+18.72%)0.03%$0 MNov 12, 2026
53MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.59,542+3,032 (+5.37%)0.03%$0 MNov 16, 2026
54Tidal Investments LLC59,274New0.03%$0 MNov 13, 2026
55Tema Etfs LLC59,274New0.03%$0 MOct 16, 2026
56MetLife Investment Management, LLC55,061-21,210 (-27.81%)0.03%$0 MNov 16, 2026
57AQR Capital Management LLC52,448New0.03%$0 MNov 16, 2026
58Barclays PLC52,168+27,468 (+111.21%)0.03%$0 MNov 6, 2026
59XTX Topco Ltd51,900New0.03%$0 MNov 16, 2026
60Voleon Capital Management LP46,019New0.03%$0 MNov 16, 2026
61Vanguard Global Advisers, LLC45,218+602 (+1.35%)0.02%$0 MNov 13, 2026
62Legal & General Group Plc43,9600 (0.00%)0.02%$0 MNov 16, 2026
63Police & Firemen's Retirement System of New Jersey36,3490 (0.00%)0.02%$0 MNov 9, 2026
64Public Employees Retirement System Of Ohio35,395New0.02%$0 MNov 16, 2026
65Manufacturers Life Insurance Company, The34,485-117 (-0.34%)0.02%$0 MNov 13, 2026
66Alliancebernstein L.P.29,7900 (0.00%)0.02%$0 MNov 16, 2026
67HarbourVest Partners LLC29,0180 (0.00%)0.02%$0 MNov 16, 2026
68BNP Paribas Financial Markets28,031+2,468 (+9.65%)0.02%$0 MNov 12, 2026
69Parametrica Management Ltd27,8400 (0.00%)0.02%$0 MOct 27, 2026
70Voya Investment Management LLC24,0670 (0.00%)0.01%$0 MNov 10, 2026
71Wells Fargo & Company/mn23,964-124,951 (-83.91%)0.01%$0 MNov 16, 2026
72New York State Common Retirement Fund22,7000 (0.00%)0.01%$0 MNov 17, 2026
73Quadrant Private Wealth Management, LLC20,0220 (0.00%)0.01%$0 MNov 4, 2026
74Prudential Financial Inc18,5950 (0.00%)0.01%$0 MNov 16, 2026
75ProShare Advisors LLC15,474-663 (-4.11%)0.01%$0 MOct 29, 2026
76Victory Capital Management Inc14,022-79 (-0.56%)0.01%$0 MNov 10, 2026
77Centiva Capital, LP13,994New0.01%$0 MNov 13, 2026
78Legato Capital Management LLC12,423New0.01%$0 MNov 10, 2026
79CIBC Bancorp USA Inc.12,184New0.01%$0 MNov 13, 2026
80Xponance LLC11,565-204 (-1.73%)0.01%$0 MNov 3, 2026
81Qube Research & Technologies Ltd11,418New0.01%$0 MNov 13, 2026
82Ameritas Investment Partners, Inc.11,1850 (0.00%)0.01%$0 MNov 13, 2026
83Susquehanna International Group, LLP10,605-105,187 (-90.84%)0.01%$0 MNov 16, 2026
84Russell Investments Group, Ltd.10,258+403 (+4.09%)0.01%$0 MNov 6, 2026
85FNY Investment Advisers, LLC10,0000 (0.00%)0.01%$0 MOct 16, 2026
86Tower Research Capital LLC (TRC)7,031-5,452 (-43.68%)0.00%$0 MNov 16, 2026
87Citigroup Inc6,094-50,907 (-89.31%)0.00%$0 MNov 4, 2026
88Sterling Capital Management LLC2,431-53 (-2.13%)0.00%$0 MOct 22, 2026
89California State Teachers Retirement System1,6970 (0.00%)0.00%$0 MNov 13, 2026
90SBI Securities Co., Ltd.1,200-18 (-1.48%)0.00%$0 MOct 22, 2026
91GAMMA Investing LLC1,064New0.00%$0 MOct 8, 2026
92Nisa Investment Advisors, LLC8830 (0.00%)0.00%$0 MOct 20, 2026
93Jacobi Capital Management LLC800New0.00%$0 MNov 5, 2026
94Mark Sheptoff Financial Planning, LLC5000 (0.00%)0.00%$0 MNov 16, 2026
95Fortitude Family Office, LLC2940 (0.00%)0.00%$0 MOct 14, 2026
96Allworth Financial LP183New0.00%$0 MNov 17, 2026
97Arax Advisory Partners990 (0.00%)0.00%$0 MNov 12, 2026
98Group One Trading LLC46New0.00%$0 MNov 10, 2026
99UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC40New0.00%$0 MNov 16, 2026
100Caitong International Asset Management Co., Ltd17-18 (-51.43%)0.00%$0 MOct 29, 2026

All 102 institutional investors, with who bought and sold →

Mutual funds holding Century Therapeutics, Inc.#

61 funds hold shares worth $36 M (about 8.4% of the company). Since their previous reports 50 added shares and 0 sold, buying $20 M net.
Mutual funds holding Century Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.4.34 M$11 M2.4%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors2.90 M$7 M1.6%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.22 M$3 M0.67%<0.01%+1.5%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.34 M$3 M0.74%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors1.11 M$3 M0.61%0.02%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC560,308$1 M0.31%<0.01%+124%May 31, 2026
🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc.549,930$1 M0.30%0.20%newJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors413,323$1 M0.23%0.07%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.299,452$1 M0.16%<0.01%newJul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC230,383$1 M0.13%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC200,453$0 M0.11%<0.01%+112%May 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC172,406$0 M0.09%0.02%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC164,276$0 M0.09%<0.01%+119%May 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC163,592$0 M0.09%<0.01%newJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC131,018$0 M0.07%<0.01%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust125,318$0 M0.07%0.01%+531%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC112,474$0 M0.06%<0.01%+19%May 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP121,810$0 M0.07%<0.01%no changeJul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation90,500$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC94,822$0 M0.05%<0.01%+53%Jul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.76,004$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.79,415$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.65,179$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.63,739$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC58,625$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.45,800$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC43,232$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC37,139$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC34,920$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC27,732$0 M0.02%0.03%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS27,200$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC25,848$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP26,905$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.19,334$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC18,837$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.18,582$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC17,800$0 M<0.01%<0.01%+0.6%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC21,278$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC16,539$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC15,270$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC14,432$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.14,101$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management11,185$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC9,930$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC9,930$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC9,855$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS10,846$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC8,797$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC8,621$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP9,543$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP9,378$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC9,238$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP8,854$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP7,447$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC5,662$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC5,633$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC4,978$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC4,284$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.3,111$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC2,954$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC768$0 M<0.01%<0.01%+5.9%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 61 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Century Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$80 K
2 purchases, 2 insiders
Sold, 12 months
$72 K
19 sales, 3 insiders
Net, 12 months
$8 K
open market only
Insiders on file
16
since
$80 K-$270 K$0Feb 2024: bought $0 (0 trades), sold $23 K (5 trades)Feb 24Mar 2024: bought $0 (0 trades), sold $270 K (2 trades)Apr 2024: bought $0 (0 trades), sold $16 K (1 trades)May 2024: bought $0 (0 trades), sold $34 K (4 trades)MayJun 2024: bought $0 (0 trades), sold $29 K (2 trades)Jul 2024: bought $0 (0 trades), sold $6 K (3 trades)Aug 2024: bought $0 (0 trades), sold $2 K (2 trades)AugSep 2024: bought $8 K (1 trades), sold $0 (0 trades)Nov 2024: bought $0 (0 trades), sold $2 K (2 trades)Feb 2025: bought $0 (0 trades), sold $28 K (3 trades)FebMar 2025: bought $0 (0 trades), sold $5 K (4 trades)May 2025: bought $0 (0 trades), sold $17 K (3 trades)Jun 2025: bought $0 (0 trades), sold $4 K (4 trades)JunAug 2025: bought $0 (0 trades), sold $157 (1 trades)Sep 2025: bought $0 (0 trades), sold $645 (3 trades)Nov 2025: bought $18 K (1 trades), sold $18 K (3 trades)NovDec 2025: bought $80 K (2 trades), sold $415 (2 trades)Feb 2026: bought $0 (0 trades), sold $588 (1 trades)Mar 2026: bought $0 (0 trades), sold $45 K (4 trades)MarMay 2026: bought $0 (0 trades), sold $618 (1 trades)Jun 2026: bought $0 (0 trades), sold $11 K (4 trades)Aug 2026: bought $0 (0 trades), sold $545 (1 trades)AugSep 2026: bought $0 (0 trades), sold $10 K (4 trades)Nov 2026: bought $0 (0 trades), sold $404 (1 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Century Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Brent PfeiffenbergerPresident and CEO, DirectorShares withheld for tax-31,172$1.650$51 K3.60 MForm 4
filed Douglas CarrSVP Finance & OperationsSell-266$1.519$404502,641Form 4
filed Douglas CarrSVP Finance & OperationsSell-1,658$1.930$3 K502,907Form 4
filed Gregory RussottiSee RemarksSell-2,587$1.930$5 K509,198Form 4
filed Brent PfeiffenbergerPresident and CEO, DirectorShares withheld for tax-13,850$1.940$27 K3.63 MForm 4
filed Gregory RussottiSee RemarksSell-534$2.050$1 K511,785Form 4
filed Douglas CarrSVP Finance & OperationsSell-254$2.050$521504,565Form 4
filed Brent PfeiffenbergerPresident and CEO, DirectorShares withheld for tax-463$2.110$9773.63 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Century Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
32.0 M
36.6% of shares · 30.96 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 2.516-for-1 split

Trading halts

  • 2025-03-19 20:00 UTC, code T3, resumed 20:30 UTC

Fails to deliver

  • : 66,416 shares at $1.45
  • : 42,457 shares at $1.58
  • : 47,479 shares at $1.37
  • : 40,630 shares at $1.38
  • : 4,353 shares at $1.48

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Century Therapeutics, Inc. scorecard#

Passes 8 of the 18 checks that could be worked out: strongest in growth (3 of 4), weakest in financial health (1 of 3). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.7×Price to book 1.7× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median2.4×Price to sales 2.4× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-39.8%Free cash flow is -39.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth3 of 4
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • ✓Revenue up more than 5% a year over three years175.9%175.9% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median175.9%175.9% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-0.14 vs -1.61Diluted EPS -0.14 in fiscal 2025 against -1.61 the year before (report's currency).
    • ✓Net income higher than five years earlier-$10 M-$10 M in fiscal 2025 against -$54 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability2 of 5
    • ✗Profitable in the newest year-$10 MNet income -$10 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median-15.8%-15.8% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-6.0%-6.0% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-15.8%-15.8% in fiscal 2025 against -2573.7% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities6.0×Current ratio 5.97 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-1.74Z-score -1.74 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year10.1%Diluted shares up 10.1% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Century Therapeutics, Inc.'s statements, beside the median of Biotechnology.

Century Therapeutics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-15.8%-60.5%
Net margin-8.8%-68.9%
Return on equity-6.0%-61.0%
Revenue growth, 3 years a year175.9%12.9%
Free cash flow margin-95.9%-61.5%

3of 7on the Piotroski tests of financial strength

  • Net loss of $10 million, the 6th loss-making year in a row.
  • Free cash flow was negative: -$105 million.
  • The share count rose 10.1% in the year.

Century Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Century Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue1096.62.25.2——
Research and development9610793977640
General and administrative24333532199.5
Operating expenses1261451491399554
Operating income−17−138−147−134−95−54
Interest expense and finance costs——0.51.0r1.30.4
Other non-operating income (expense)7.613123.0−0.90.3
Income before tax−9.6−125−135−131−96−54
Income tax−0.11.81.90.10.0—
Net income including minority interests−9.6−127−137−131−96−54
Net income attributable to shareholders−9.6−127−137−131−96−54
Earnings per share, basic-0.14-1.61-2.30-2.27-2.96-7.16
Earnings per share, diluted-0.14-1.61-2.30r-2.96r-2.96-7.16
Shares, weighted average (basic)87795958327.5
Shares, weighted average (diluted)877959r32r327.5
Balance sheet
Cash and cash equivalents625847845627
Short-term investments5513112523116649
Other current assets3.74.81.64.00.30.3
Current assets12119417732022879
Property, plant and equipment506272835815
Right-of-use (leased) assets16292029129.4
Other intangible assets3434————
Long-term investments—3189521361.1
Total assets224353361487437107
Accounts payable4.83.12.75.57.68.1
Debt due within a year———6.51.0—
Current liabilities2013018301612
Long-term debt———3.78.99.6
Lease liabilities (non-current)404947391512
Total liabilities651921761844133
Retained earnings−792−782−656−519−388−292
Shareholders' equity159161185303396−106
Total liabilities and equity224353361487437107
Shares outstanding88866055r58r7.5
Cash-flow statement
Share-based compensation6.81315114.70.9
Cash from operating activities−104−110−8814−89−41
Capital expenditure−0.8−0.2−14−31−45−9.8
Cash from investing activities1084761−13−298−23
Debt repaid——−10———
Shares issued0.20.10.50.30.2—
Cash from financing activities0.275−9.72741848
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Century Therapeutics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Single reportable segment$109 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Century Therapeutics, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.

Century Therapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office2 subsidiaries—
🇳🇱 Netherlands1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Century Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Restructuring 1 · Directors and officers 7 · Material agreement 1 · Agreement ended 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 10

Century Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Delisting notice8-K
Directors and officersResults announced8-K
RestructuringDirectors and officers8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Agreement ended8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 acquisitions, $40 M paid where reported

Businesses it acquired

Acquisitions by Century Therapeutics, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
Clade Therapeutics, Inc2024—$40 M—Annual report

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Century Therapeutics, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $120 K a year.

Certified, FY2026
1
#1,871 among companies on value.today
Worker positions
1
Median wage offered
$120 K
a year, full-time
Applications filed
1
Century Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Associate Scientist, Discovery BiologyBioinformatics Scientists1$120 K

Where: Watertown, MA 1

Century Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202611$120 K1
FY202511$85 K1
FY202211$129 K1
FY202044$85 K4

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Century Therapeutics LLC

Layoffs at Century Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2025–2025
Latest
—
2025-07-01
Century Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025············—
Century Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
51% of workforceRestructuring planSEC 8-K“The Company expects to implement a net reduction of its employee headcount by approximately 51% (the “ RIF ”).”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Century Therapeutics, Inc. compares in Biotechnology

  • Market cap$263 M · higher than 49% of 726
  • Revenue$109 M · higher than 69% of 647
  • Net margin-8.8% · higher than 65% of 408
  • Revenue growth1556.5% · higher than 99% of 438
  • Price / sales2.4× · lower than 81% of 339
  • Price / book1.7× · lower than 63% of 534
  • FCF yield-39.8% · higher than 29% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Century Therapeutics, Inc.🇺🇸$263 M—-8.8%+1556.5%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 1, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Century Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Century Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Century Therapeutics, Inc.? Suggest a correction